Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).

Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 2019 Sep 14;: Authors: Westerouen van Meeteren MJ, Drenth JPH, Tjwa ETTL Abstract Introduction: Non-alcoholic fatty liver disease (NAFLD) encompasses a progressive disease phenotype starting from simple steatosis, which can progress to nonalcoholic steatohepatitis (NASH). It is component of the metabolic syndrome with a large impact on mortality in these patients. PPARs are nuclear receptors that regulate lipid and insulin metabolism, two key components in pathophysiology of NAFLD and NASH. Elafibranor acts as an agonist of PPAR-α and PPAR-δ and is currently under development for the treatment of NAFLD. Areas covered: This review summarizes the pharmacological aspects, the pre-clinical and clinical effectivity and safety data of elafibranor for the treatment of non-alcoholic steatohepatitis and fibrosis. Expert opinion: Current data support an effect of elafibranor on the resolution on NASH and the improvement of two key drivers of NASH progression; insulin resistance and serum lipid normalization. The safety profile is favorable, though reversible serum creatinine elevations occurs with use, potentially limiting its use in patients with concurrent renal disease. The modest effect sizes in different NAFLD disease stages, of elafibranor and other drugs in development for NASH, will likely lead to a pursue of drug combi...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research